Illumina prevails against BGI at English High Court
21-01-2021
Illumina to acquire Jeff Bezos-backed cancer testing company
23-09-2020
Illumina secures injunction against BGI
18-06-2020
Sundry Photography / Shutterstock.com
Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BGI, Illumina, genetics, sequencing, DNA, injunction, Northern California, appeal
